Delivery Order V797D70252-36C26025F0137
Award Date
1/28/25
Potential Completion Date
2/18/25
Potential Value
$3.9K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Gilead Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Dublin, OH 43017, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of SUNLENCA 300MG TAB,PKT,4 to the U.S. Department of Veterans Affairs (VA) through the Veterans Integrated Service Network (VISN) 20. The prime contractor is Gilead Sciences Inc., doing business as Gilead, a prominent biopharmaceutical company. The contract has a ceiling value of $3,105.62 and is a firm fixed-price delivery order under Gilead's GSA Schedule 61-IB contract for Pharmaceuticals and Drugs. This contract does not have a small...
This federal contract award is for the delivery of VEKLURY REMDESIVIR 437, an emergency pharmaceutical supply, to the Veterans Integrated Service Network 23 (VISN 23) of the U.S. Department of Veterans Affairs (VA). The $89,916.75 firm fixed-price delivery order was awarded to Gilead Sciences Inc., a large biopharmaceutical company, under the GSA Schedule 61-IB for Pharmaceuticals and Drugs. This contract does not have a set-aside designation. Gilead holds a $29.16 million Blanket Purchase...
This federal contract award is for the delivery of SULENCA INJ, a pharmaceutical product, to the U.S. Department of Veterans Affairs (VA) through Gilead Sciences Inc., the prime contractor. The contract has a ceiling value of $14,937.69 and was awarded on September 12, 2024 as a firm-fixed-price delivery order under Gilead's General Services Administration (GSA) Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has an ultimate completion date of September 13, 2024 and was...
This is a federal contract awarded by the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead), a prominent biopharmaceutical company. The contract, valued at $307,511.22, is a delivery order under Gilead's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. It provides the VA's Veterans Integrated Service Network (VISN) with the cancer immunotherapy drug YESCARTA. The contract has an ultimate completion date of October 31, 2023. Gilead is the...
This is a federal delivery order contract awarded by the Veterans Integrated Service Network (VISN) 16 of the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc., a large biopharmaceutical company. The contract is for the supply of Veklury (remdesivir), a COVID-19 treatment medication. The contract has a ceiling value of $77,850.00 and was awarded on December 23, 2020, with a completion date of January 22, 2021. The contract was awarded under GSA Schedule 61-IB for Pharmaceuticals...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded Gilead Sciences Inc. a $136,237.50 firm-fixed-price delivery order contract for Veklury (remdesivir), a COVID-19 treatment. This order was placed against Gilead's existing Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Gilead, a biopharmaceutical company, is the prime contractor and will directly provide the medication, with performance taking place in Foster City, California. This...
This federal contract award is for the delivery of REMDESIVIR 100MG/VIAL INJ to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22. The contract was awarded to the prime contractor Gilead Sciences Inc., a for-profit biopharmaceutical manufacturer, on December 3, 2020, with a potential value of $140,130.00. The contract has a completion date of December 11, 2020 and is categorized under the Coronavirus COVID-19 National Interest Action Code....
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Gilead Sciences Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The order is for Veklury (remdesivir) to treat COVID-19, with a potential value of $194,625.00. As a Firm Fixed Price contract, Gilead will deliver the pharmaceutical product directly to VA medical facilities in Carrollton, TX. The award is not associated with a set-aside designation....
This is a delivery order under the GSA Schedule 61-IB for Pharmaceuticals and Drugs, awarded by the U.S. Department of Veterans Affairs (VA) to Gilead Sciences Inc. (Gilead) for the COVID-19 treatment Veklury (remdesivir). The $77,850 fixed-price contract has a performance period ending on March 31, 2021. Gilead, a large biopharmaceutical company, is the sole-source manufacturer of Veklury and a key supplier of critical medications to federal healthcare programs, particularly the VA. The...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Gilead Sciences Inc., a biopharmaceutical company, for the supply of the COVID-19 antiviral medication Veklury (remdesivir). The order has a firm-fixed price of $155,700.00 and a completion date of October 29, 2021. The contract was awarded on December 9, 2020 and is placed under Gilead's existing General Services Administration (GSA) Multiple Award Schedule contract for...